Skip to main content
Clinical Trials/EUCTR2018-001466-42-FR
EUCTR2018-001466-42-FR
Active, not recruiting
Phase 1

EFFECTIVENESS OF INTRANASAL DEXMEDETOMIDINE FOR SEDATEDAUDITORY BRAINSTEM RESPONSE TESTING - DEXMEDETOMIDINE - ABR

Fondation Lenval - Hôpitaux Pédiatriques de Nice CHULENVA0 sites60 target enrollmentApril 19, 2018

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Child requiring auditory evaluation in a context of suspicion of deafness, language delay, overall developmental delay, risk factors for hearing loss.
Sponsor
Fondation Lenval - Hôpitaux Pédiatriques de Nice CHULENVA
Enrollment
60
Status
Active, not recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 19, 2018
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Fondation Lenval - Hôpitaux Pédiatriques de Nice CHULENVA

Eligibility Criteria

Inclusion Criteria

  • \-Child aged 1 to 15 years old
  • \-ASA 1 or 2 (American Society Anesthesiologists scale patient)
  • \-Need to evaluate the child audition in a context of suspicion of
  • deafness, delay of language, global delay of the development, the risk
  • factors of hearing loss
  • \-Impossibility to realize a hearing test by conventional audiogram or
  • behavioral due to a cognitive or behavioral disorder of the child
  • \-Affiliation to social security scheme
  • \-Signature of the authorization documents of the 2 parents or the
  • representative of the parental authority for the participation of the child

Exclusion Criteria

  • \- Heart disease or heart rhythm disorder
  • \- Pneumopathy or asthmatic crisis in previous 2 weeks in the
  • examination
  • \- Recent used of digoxine or beta\-blocker
  • \- Use of anti\-epileptic or psychotropic drugs
  • \- Medical history of sleep apnea
  • \- Receptor alpha2 agonist allergy
  • \- Gastrooesophageal reflux disease
  • \- Upper airway abnormality
  • \- Acute cerebrovascular diseases

Outcomes

Primary Outcomes

Not specified

Similar Trials